Tuesday, 18 February 2020

Agios receives nod for ivosidenib

23 July 2018 | News

Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.

Singapore – The FDA approves Agios Pharmaceuticals' TIBSOVO (ivosidenib) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.

Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account